Fritz-Rdzanek Anna, Grzybowski Wojciech, Beta Jarosław, Durczyński Andrzej, Jakimiuk Artur
Department of Obstetrics and Gynecology, Central Clinical Hospital of Ministry of Interior and Administration, 02-507 Warsaw.
Oncol Lett. 2012 Sep;4(3):385-389. doi: 10.3892/ol.2012.757. Epub 2012 Jun 13.
Epithelial ovarian cancer has the highest mortality of all gynecological cancers, and its progression is often without symptoms. Clinical outcome and survival may be improved if the disease is identified in the early stages. The objective of the study was to evaluate the utility of the serum biomarkers human epididymis protein 4 (HE4), soluble mesothelin-related protein (SMRP) and CA125 in the detection of ovarian cancer. In this retrospective study, the serum concentrations of CA125, HE4 protein and SMRP were measured in a cohort of 70 patients with epithelial ovarian cancer (EOC) compared with 78 healthy controls. Median serum levels of CA125 for ovarian cancer cases were 503.55±560.7 U/ml vs. 9.28±14.47 U/ml in the control group (p<0.001); for SMRP 5.13±7.64 nM vs. 1.02±0.89 nM (p<0.01); and for HE4 597.95±934.59 pM vs. 56.75±43.79 pM (p<0.001), respectively. Positive correlations between the clinical stage of EOC and CA125, HE4 and SMRP serum concentrations were found [(R=0.83; p<0.001); (R=0.64; p<0.001); (R=0.45; p<0.001), respectively]. Data analysis for the whole study group also revealed a significant correlation between plasma concentrations of CA125 and HE4 (R=0.45; p<0.001), between CA125 and SMRP (R=0.38; p<0.001) as well as HE4 and SMRP (R=0.51; p<0.001). Similar significant correlations between serum biomarker concentrations were also found in the ovarian cancer group [CA125 and HE4 (R=0.31; p<0.01); CA125 and SMRP (R=0.25; p<0.05); HE4 and SMRP (R=0.44, p<0.001), respectively]. A significant correlation was observed between the serous histological type of EOC and serum concentration of HE4 in the study group compared with other non-serous types of ovarian cancer (p<0.01). In conclusion, measuring CA125 in combination with new biomarkers such as SMRP and HE4 may improve the accuracy of ovarian cancer diagnosis, particularly in early detection of the disease.
上皮性卵巢癌在所有妇科癌症中死亡率最高，且其进展通常没有症状。如果在疾病早期被发现，临床结局和生存率可能会得到改善。本研究的目的是评估血清生物标志物人附睾蛋白4（HE4）、可溶性间皮素相关蛋白（SMRP）和CA125在卵巢癌检测中的效用。在这项回顾性研究中，对70例上皮性卵巢癌（EOC）患者和78名健康对照者的队列进行了CA125、HE4蛋白和SMRP的血清浓度测定。卵巢癌病例的CA125血清中位水平为503.55±560.7 U/ml，而对照组为9.28±14.47 U/ml（p<0.001）；SMRP分别为5.13±7.64 nM和1.02±0.89 nM（p<0.01）；HE4分别为597.95±934.59 pM和56.75±43.79 pM（p<0.001）。发现EOC的临床分期与CA125、HE4和SMRP血清浓度之间存在正相关[分别为（R=0.83；p<0.001）；（R=0.64；p<0.001）；（R=0.45；p<0.001）]。对整个研究组的数据分析还显示，CA125与HE4的血浆浓度之间存在显著相关性（R=0.45；p<0.001），CA125与SMRP之间（R=0.38；p<0.001）以及HE4与SMRP之间（R=0.51；p<0.001）也存在显著相关性。在卵巢癌组中，血清生物标志物浓度之间也发现了类似的显著相关性[CA125与HE4（R=0.31；p<0.01）；CA125与SMRP（R=0.25；p<0.05）；HE4与SMRP（R=0.44，p<0.001），分别]。与其他非浆液性卵巢癌类型相比，研究组中EOC的浆液性组织学类型与HE4血清浓度之间存在显著相关性（p<0.01）。总之，联合检测CA125与SMRP和HE4等新的生物标志物可能会提高卵巢癌诊断的准确性，特别是在疾病的早期检测中。
